Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Biran, Noa [1 ]
Vesole, David H. [1 ]
Zhang, Shijia [2 ]
Richter, Joshua R. [1 ]
Kuo, Yen-Hong [3 ]
Schmidt, Linda [1 ]
McBride, Laura [1 ]
Anand, Palka [1 ]
Ivanovski, Kristin [1 ]
Pierre, Amy
Kumka, Susan [1 ]
Cuccurullo, Carmela [1 ]
Siegel, David S. [1 ]
机构：
[1] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Rutgers New Jersey Med Sch, Dept Med, Newark, NJ USA
[3] Jersey Shore Univ Med Ctr, Dept Res, Neptune, NJ USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5685.5685
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5685
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the Flatiron database
    Dhakal, Binod
    Einsele, Hermann
    Schecter, Jordan
    Deraedt, William
    Lendvai, Nikoletta
    Slaughter, Ana
    Lonardi, Carolina
    Nair, Sandhya
    He, Jianming
    Voelker, Jennifer
    Cost, Patricia
    Valluri, Satish
    Pacaud, Lida
    Yalniz, Fevzi
    Yong, Kwee
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S168 - S168
  • [42] Real-World Outcomes in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) With Prior Proteasome Inhibitor and Lenalidomide Exposure in Sweden
    Luong, Vincent
    Kashif, Muhammad
    Uttervall, Katarina
    Bohlin, Anna
    Fernstrom, Annette Oster
    Qu, Ying
    Lee, Seina
    Mendes, Joao
    Van Hoorenbeeck, Sandra
    Franck, Eva Hellqvist
    He, Jianming
    Alici, Evren
    Lund, Johan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S269 - S270
  • [43] Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma
    Ji Hyun Lee
    Sung-Hyun Kim
    Hye Ryeon Kim
    Chang-Ki Min
    Je-Jung Lee
    Ho-Jin Shin
    Jae-Cheol Jo
    Ji Yun Lee
    Joon Ho Moon
    Kihyun Kim
    International Journal of Hematology, 2023, 117 : 225 - 235
  • [44] Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma
    Sokol, Juraj
    Guman, Tomas
    Chudej, Juraj
    Hlebaskova, Monika
    Stecova, Natalia
    Valekova, Lubica
    Kucerikova, Monika
    Stasko, Jan
    ANNALS OF HEMATOLOGY, 2022, 101 (01) : 81 - 89
  • [45] Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma
    Garcia-Guinon, Antoni
    Charry, Paola Andrea
    Jimenez, Maria
    Sarra, Josep
    Delgado, Izarbe
    de la Torre, Laura Segura
    Santaliestra, Marta
    Garcia-Pintos, Marta
    Gonzalez, Yolanda
    Senin, Alicia
    Motllo, Cristina
    Abella, Eugenia
    Cabezudo, Elena
    Granell, Miquel
    Sancho, Esther
    Herranz, Maria Jose
    Seres, Yasmina
    Gironella, Mercedes
    Soler, Juan Alfons
    Marti-Tutusaus, Josep Maria
    Ben Azaiz, Ran
    de Larrea, Carlos Fernandez
    ANNALS OF HEMATOLOGY, 2025, 104 (02) : 1177 - 1186
  • [46] Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients
    Lovas, Szilvia
    Varga, Gergely
    Farkas, Peter
    Masszi, Tamas
    Wohner, Nikolett
    Bereczki, Agnes
    Adamkovich, Nora
    Borbenyi, Zita
    Szomor, Arpad
    Alizadeh, Hussain
    Szaleczky, Erika
    Wolf, Krisztina
    Schneider, Tamas
    Plander, Mark
    Szendrei, Tamas
    Csacsovszki, Otto
    Csukly, Zoltan
    Rajnics, Peter
    Egyed, Miklos
    Nagy, Zsolt
    Rejto, Laszlo
    Illes, Arpad
    Mikala, Gabor
    Varoczy, Laszlo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (05) : 559 - 565
  • [47] Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients
    Szilvia Lovas
    Gergely Varga
    Péter Farkas
    Tamás Masszi
    Nikolett Wohner
    Ágnes Bereczki
    Nóra Adamkovich
    Zita Borbényi
    Árpád Szomor
    Hussain Alizadeh
    Erika Szaleczky
    Krisztina Wolf
    Tamás Schneider
    Márk Plander
    Tamás Szendrei
    Ottó Csacsovszki
    Zoltán Csukly
    Péter Rajnics
    Miklós Egyed
    Zsolt Nagy
    László Rejtő
    Árpád Illés
    Gábor Mikala
    László Váróczy
    International Journal of Hematology, 2019, 110 : 559 - 565
  • [48] Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Shaikh, Hira
    Lochner, Jonathan
    Friend, Reed
    Snyder, Jordan
    Davis, James
    Patrus, Gina
    Dileo, Rachel
    Ahmed, Nausheen
    Mewawalla, Prerna
    Poonsombudlert, Kittika
    Struble, Emily
    Wolcott, Allyson
    Green, Kimberly
    Sparrow, Samantha
    Mushtaq, Muhammad Umair
    Paul, Barry
    Abdallah, Al-Ola
    Strouse, Christopher
    Hashmi, Hamza
    Atrash, Shebli
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S87 - S88
  • [49] Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Sannareddy, Aishwarya
    Shaikh, Hira
    Mahmoudjafari, Zahra
    Khouri, Jack
    Kaur, Gurbakhash
    Strouse, Christopher
    Valent, Jason
    Larry, Anderson D., Jr.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [50] Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma
    Juraj Sokol
    Tomas Guman
    Juraj Chudej
    Monika Hlebaskova
    Natalia Stecova
    Lubica Valekova
    Monika Kucerikova
    Jan Stasko
    Annals of Hematology, 2022, 101 : 81 - 89
12345